Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypothalamus Amyloid Levels Are Associated with Early Sex-Dependent Alterations in Peripheral Energy Homeostasis in TgF344-AD Rats.

Molecular neurobiology·2026
Same author

Hypothalamus amyloid levels are associated with early sex-dependent alterations in energy homeostasis in TgF344-AD rats.

bioRxiv : the preprint server for biology·2026
Same author

Methionine restriction provides sex-specific protection against high-fat diet-induced adiposity, peripheral insulin resistance, and neuroinflammation in FGF21-dependent and independent manners in mice.

PloS one·2026
Same author

Prevention and Reversal of Hypertension-Induced Coronary Microvascular Dysfunction by a Plant-Based Diet.

Journal of the American Heart Association·2025
Same author

Survey Validation of Exercise and Body Composition Testing and Exercise Training Programs for People With Cystic Fibrosis: A Delphi Study.

Pediatric pulmonology·2025
Same author

Prevention and reversal of hypertension-induced coronary microvascular dysfunction by a plant-based diet.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: May 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Lipid-lowering drugs and circulating adiponectin.

Desiree Wanders1, Eric P Plaisance, Robert L Judd

  • 1Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA.

Vitamins and Hormones
|September 29, 2012
PubMed
Summary

Lipid-lowering drugs improve cardiovascular health by affecting blood lipids and adiponectin (a protein from fat tissue). This analysis explores how statins, fibrates, niacin, and omega-3s impact adiponectin levels and related mechanisms.

More Related Videos

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

Related Experiment Videos

Last Updated: May 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

Area of Science:

  • Endocrinology
  • Cardiovascular Pharmacology
  • Metabolic Syndrome

Background:

  • Primary and combined hyperlipidemia increase cardiovascular disease (CVD) risk.
  • Lipid-lowering drugs reduce CVD morbidity and mortality, primarily through improved lipid profiles.
  • Pleiotropic effects of these drugs, beyond lipid reduction, are increasingly recognized.

Purpose of the Study:

  • To comprehensively analyze the impact of major lipid-lowering drug classes on circulating adiponectin.
  • To elucidate the mechanisms underlying the relationship between lipid reduction and adiponectin concentrations.
  • To review the known effects of statins, fibrates, niacin, and omega-3 fatty acids on adiponectin.

Main Methods:

  • Literature review and analysis of existing studies.
  • Examination of pharmacological agents including statins, fibrates, niacin, and omega-3 fatty acids.
  • Investigation of circulating adiponectin levels as a key biomarker.

Main Results:

  • A significant relationship exists between pharmacological lipid reduction and circulating adiponectin levels.
  • Adiponectin, secreted by adipose tissue, influences hepatic glucose production, fatty acid oxidation, and vascular inflammation.
  • Different drug classes demonstrate varying effects on adiponectin concentrations.

Conclusions:

  • Lipid-lowering therapies modulate adiponectin, contributing to their pleiotropic cardiovascular benefits.
  • Understanding these effects is crucial for optimizing hyperlipidemia treatment strategies.
  • Further research into adiponectin-mediated mechanisms can enhance therapeutic outcomes.